AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-18 and is reviewed periodically as new material appears.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== History == Orinase was developed by Upjohn Co. at a time when the primary medical treatment for diabetes was insulin injections. Eli Lilly had a lock on the market for insulin production at the time. The practical applicability of Orinase, like that of other treatments for disease states detected by paraclinical signs (such as lab test results) rather than clinically observable signs or patient-reported symptoms, benefited from increased sensitivity and availability of testing (in this instance, urinary glucose testing and later also fingerstick blood glucose testing). Milton Moskowitz (editor in 1961 of Drug and Cosmetic Industry) claimed that the introduction of Orinase, "expanded the total market by bringing under medical care diabetics who were formerly not treated." It did this by changing the mindset about diabetes even more than insulin had. Treatment of this chronic disease was no longer seen as a mere slowing of "inexorable degeneration", but instead viewed through "a model of surveillance and early detection." Orinase and other sulfonylureas emerged from European pharmaceutical research into antibiotics, specifically from attempts to develop sulfa compounds. One of the contenders for a new sulfa antibiotic had serious side effects during clinical trials at the University of Montpellier including blackouts, convulsions, and coma, side effects not observed with any other drugs in the sulfa cohort. An insulin researcher at the same university heard of these side effects and recognized them as common results of hypoglycemia.
===== Serpentes (Snakes) ===== Clade Scolecophidia (Blindsnakes) Family Typhlopidae Anilios bituberculatus, Prong-snouted blind snake (2021) Indotyphlops braminus, Brahminy blindsnake, (2022) Clade Booidea Family Pythonidae Morelia viridis, Green Tree Python (2022) Python bivittatus, Burmese python (2013) Python regius, Ball python (2020) Simalia boeleni, Boelen's Python (2022) Family Boidae Boa constrictor, Boa constrictor (2019) Charina bottae, Rubber boa, (2022) Clade Caenophidia Family Viperidae Azemiops feae, Fea's viper (2022) Bothrops jararaca, Jararaca lancehead, (2021) Crotalus adamanteus, Eastern diamondback rattlesnake (2021) Crotalus mitchellii pyrrhus, southwestern speckled rattlesnake (2014) Crotalus oreganus helleri, southern Pacific rattlesnake (2023) Crotalus tigris, Tiger rattlesnake (2021) Crotalus viridis, Great Plains rattlesnake (2018) Daboia siamensis, Eastern Russell's viper (2022) Deinagkistrodon acutus, Five-pacer viper (2016) Protobothrops flavoviridis, Okinawa Habu (2018) Protobothrops mucrosquamatus, Taiwanese Habu (2017, 2024) Trimeresurus albolabris, White-lipped tree pit viper (2024) Cerastes gasperetti, Arabian horned viper (2025) Family Homalopsidae Myanophis thanlyinesis, (No common name), (2021) Family Colubridae Ahaetulla prasina, Asian vine snake (2023) Arizona elegans occidentalis, California glossy snake (2022) Chrysopelea ornata, Ornate Flying Snake (2023) Diadophis punctatus, ring-necked snake (2023) Dolichophis caspius, Caspian whipsnake (2020) Elaphe carinata, King ratsnake (2024) Pantherophis guttatus, corn snake (2014) Pantherophis obsoletus, Leucistic Texas Rat Snake (2021) Ptyas mucosa, Oriental rat snake (2024) Thamnophis sirtalis, Common garter snake (2018) Thermophis baileyi, Tibetan hot-spring snake (2018) Family Elapidae Bungarus multicinctus, Many-banded krait (2022) Emydocephalus ijimae, Ijima's turtle-headed sea snake, (2019) Hydrophis curtus, Shaw's Sea Snake (2020) Hydrophis cyanocinctus, blue-banded sea snakes (2021) Hydrophis melanocephalus, slender-necked sea snake, (2019) Laticauda colubrina, yellow-lipped sea krait, (2019) Laticauda laticaudata, blue-lipped sea krait, (2019) Naja atra, Chinese cobra (2024) Naja naja, Indian cobra (2020) Notechis scutatus, mainland tiger snake (2022) Ophiophagus hannah, king cobra (2013) Pseudonaja textilis, eastern brown snake (2022)
Calliphoridae (blowflies) Some examples include Calliphora vomitoria, Calliphora vicina, and Cordylobia Oestridae (botflies) Sarcophagidae (fleshflies) Sarcophaga barbata are usually found in dead and rotting meat and animal excrement, which are prime environments for them. This is because their larvae are facultative parasites, as they feed on organic tissue and use the hosts' oxygen reserve. Other families occasionally involved are:
Sources: en.wikipedia.org
=== Nutritional value === House crickets are an incomplete protein source, deficient in tryptophan and lysine. They contain both omega-3 and omega-6 fatty acids. Despite their nutritional value, insects such as house crickets are not widely accepted as food in Western countries. Surveys have found that while many people are willing to try plant-based meat substitutes, only a small proportion would consider eating insects.
Engineers have been able to successfully incorporate the AceA and AceB genes into mammalian cells in culture, and the cells were successful in translating and transcribing the genes into the appropriate enzymes, proving that the genes could successfully be incorporated into the cell's DNA without damaging the functionality or health of the cell. However, being able to engineer the pathway into transgenic mice has proven to be difficult for engineers. While the DNA has been expressed in some tissues, including the liver and small intestine in test animals, the level of expression is not high, and not found to be statistically significant. In order to successfully engineer the pathway, engineers would have to fuse the gene with promoters which could be regulated in order to increase the level of expression, and have the expression in the right cells, such as epithelial cells. Efforts to engineer the pathway into more complex animals, such as sheep, have not been effective. This illustrates that much more research needs to be done on the topic, and suggests it is possible that a high expression of the cycle in animals would not be tolerated by the chemistry of the cell. Incorporating the cycle into mammals will benefit from advances in nuclear transfer technology, which will enable engineers to examine and access the pathway for functional integration within the genome before its transfer to animals. There are possible benefits, however, to the cycle's absence in mammalian cells.
=== Distribution === From 1977 to 1981, SOLAR was distributed by RCA Records, which had also distributed the Soul Train Records label during its two-year run. Griffey formed a second label, Constellation Records (no relation to the Chicago-based indie label founded by Ewart Abner) in 1981, which focused on more contemporary and top forty-geared acts to Griffey's more traditionally "urban" establishment (including Jon Gibson and Klymaxx). Upon its formation, Constellation was distributed through Elektra/Asylum Records, making it only natural for the main SOLAR label to jump ship to Elektra for distribution when it left RCA. In the meantime, the Constellation label moved to MCA Records for distribution in 1984. Shortly thereafter, Griffey decided to abandon contemporary music to focus all of his attention on running SOLAR, and retaining its sonic theme. Subsequently, MCA bought the Constellation imprint and absorbed its artists, including Klymaxx, which had been its biggest act. SOLAR's relationship with Elektra lasted until 1986. After the Elektra distribution deal expired, SOLAR briefly took up distribution with Capitol Records until 1989, at which time it signed a new distribution deal with Epic Records, which oversaw what would ultimately become its twilight years. In the early 1990s, the label released its last recordings- 1991's Now by Richie Havens and Times 3's eponymous debut album, the soundtrack to the 1992 film Deep Cover, 3rd Avenue's 1992 debut album Let's Talk About Love, and 1993 The Deele album An Invitation To Love.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.